Millipore Sigma Vibrant Logo

324880 (–)-Epigallocatechin Gallate - CAS 989-51-5 - Calbiochem

One of the main polyphenolic constituents of green tea that exhibits potent antitumor, anti-inflammatory, and antioxidant properties.

(–)-Epigallocatechin Gallate - CAS 989-51-5 - Calbiochem: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。

同義語: EGCG, (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate), HAT Inhibitor X, Histone Acetyltransferase Inhibitor X, p300/CBP Inhibitor VIII, PCAF Inhibitor V, DNA MTase Inhibitor IV, DNA Methyltransferase Inhibitor IV

Primary Target: PMA-induced skin thickening
View This Product on Sigma-Aldrich
324880
価格＆在庫状況を照会

概要

Replacement Information

主要スペック表

CAS #Empirical Formula
989-51-5C₂₂H₁₈O₁₁

価格＆在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
324880-10MGCN
在庫状況検索中…
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      		 樹脂ｱﾝﾌﾟﾙ 10 mg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示　
      値引
      ()
       
      —
      弊社照会
      		 —
      Description
      OverviewOne of the main polyphenolic constituents of green tea that exhibits potent antitumor, anti-inflammatory, and antioxidant properties. Arrests cell cycling at G0/G1 phase and induces apoptosis in a dose-dependent manner. Shown to inhibit PMA-induced skin thickening and to activate of protein kinase C. Also activates ornithine decarboxylase and interleukin-1α mRNA and protein expression. Acts as an inhibitor of inducible nitric oxide synthase (iNOS) gene expression and enzyme activity. Also blocks peroxynitrite-mediated formation of 8-oxodeoxyguanosine and 3-nitrotyrosine. Strongly and directly inhibits telomerase in cell-free systems and in cancer cell lines. An inhibitor of Dnmt1 (IC50 = 210-470 nM). Acts as a selective and noncompetitive inhibitor of HAT activities (IC50 = 30, 50, 60 and 70 µM for p300, CBP, PCAF and TIP60) with minimal effects on HDAC, SIRT and HMTase.
      Catalogue Number324880
      Brand Family Calbiochem®
      SynonymsEGCG, (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate), HAT Inhibitor X, Histone Acetyltransferase Inhibitor X, p300/CBP Inhibitor VIII, PCAF Inhibitor V, DNA MTase Inhibitor IV, DNA Methyltransferase Inhibitor IV
      References
      ReferencesChoi, K.C., et al. 2009. Cancer Res. 69, 583.
      Dell'Aicia, I., et al. 2004. EMBO reports 5, 1.
      Tachibana, H., et al. 2004. Nat. Struct. Mol. Biol. 11, 380.
      Naasami, I., et al. 1998. Biochem. Biophys. Res. Commun. 249, 391.
      Ahmad, N., et al. 1997. J. Natl. Cancer 89, 1881.
      Chan, M.M.-Y., et al. 1997. Biochem. Pharmacol. 54, 1281.
      Lin, Y.-L., and Lin, J.-K. 1997. Mol. Pharmacol. 52, 465.
      Fiala, E.S., et al. 1996. Experientia 52, 922.
      Katiyar, S.K., et al. 1995. J. Invest. Dermatol. 105, 394.
      Liao, S., et al. 1995. Cancer Lett. 96, 239.
      Yamane, T., et al. 1995. Cancer Res. 55, 2081.
      Huang, M.T., et al. 1992. Carcinogenesis 13, 947.
      Product Information
      CAS number989-51-5
      ATP CompetitiveN
      FormFaint pink solid
      Hill FormulaC₂₂H₁₈O₁₁
      Chemical formulaC₂₂H₁₈O₁₁
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetPMA-induced skin thickening
      Primary Target IC<sub>50</sub>210-470 nM against Dnmt1; 30, 50, 60 and 70 µM for p300, CBP, PCAF and TIP60
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSKB5200000
      Safety Information
      R PhraseR: 36/37/38

      Irritating to eyes, respiratory system and skin.
      S PhraseS: 26-36

      In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
      Wear suitable protective clothing.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Irritant
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze at -20°C. DMSO stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      324880-10MGCN 04055977196092

      Documentation

      (–)-Epigallocatechin Gallate - CAS 989-51-5 - Calbiochem (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      (–)-Epigallocatechin Gallate - CAS 989-51-5 - Calbiochem 試験成績書（CoA）

      タイトルロット番号
      324880

      参考資料

      参考資料の概要
      Choi, K.C., et al. 2009. Cancer Res. 69, 583.
      Dell'Aicia, I., et al. 2004. EMBO reports 5, 1.
      Tachibana, H., et al. 2004. Nat. Struct. Mol. Biol. 11, 380.
      Naasami, I., et al. 1998. Biochem. Biophys. Res. Commun. 249, 391.
      Ahmad, N., et al. 1997. J. Natl. Cancer 89, 1881.
      Chan, M.M.-Y., et al. 1997. Biochem. Pharmacol. 54, 1281.
      Lin, Y.-L., and Lin, J.-K. 1997. Mol. Pharmacol. 52, 465.
      Fiala, E.S., et al. 1996. Experientia 52, 922.
      Katiyar, S.K., et al. 1995. J. Invest. Dermatol. 105, 394.
      Liao, S., et al. 1995. Cancer Lett. 96, 239.
      Yamane, T., et al. 1995. Cancer Res. 55, 2081.
      Huang, M.T., et al. 1992. Carcinogenesis 13, 947.

      カタログ

      タイトル
      Caspases and other Apoptosis Related Tools Brochure
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision05-August-2009 JSW
      SynonymsEGCG, (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate), HAT Inhibitor X, Histone Acetyltransferase Inhibitor X, p300/CBP Inhibitor VIII, PCAF Inhibitor V, DNA MTase Inhibitor IV, DNA Methyltransferase Inhibitor IV
      DescriptionOne of the main polyphenolic constituents of green tea that possesses potent antitumor, anti-inflammatory, and antioxidant properties. EGCG has been shown to inhibit PMA-induced skin thickening, activation of protein kinase C, activation of ornithine decarboxylase, and activation of interleukin-1α mRNA and protein expression. Has also been shown to inhibit inducible nitric oxide synthase (iNOS) gene expression and enzyme activity and to inhibit the peroxynitrite-mediated formation of 8-oxodeoxyguanosine and 3-nitrotyrosine. Also strongly and directly inhibits telomerase. Acts as a selective and noncompetitive inhibitor of HAT activities (IC50 = 30, 50, 60 and 70 µM for p300, CBP, PCAF and TIP60) with minimal effects on HDAC, SIRT and HMTase.
      FormFaint pink solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number989-51-5
      RTECSKB5200000
      Chemical formulaC₂₂H₁₈O₁₁
      Structure formulaStructure formula
      Purity≥95% by HPLC
      SolubilityDMSO or H₂O (5 mg/ml)
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze at -20°C. DMSO stock solutions are stable for up to 3 months at -20°C.
      Toxicity Irritant
      Merck USA index14, 3526
      ReferencesChoi, K.C., et al. 2009. Cancer Res. 69, 583.
      Dell'Aicia, I., et al. 2004. EMBO reports 5, 1.
      Tachibana, H., et al. 2004. Nat. Struct. Mol. Biol. 11, 380.
      Naasami, I., et al. 1998. Biochem. Biophys. Res. Commun. 249, 391.
      Ahmad, N., et al. 1997. J. Natl. Cancer 89, 1881.
      Chan, M.M.-Y., et al. 1997. Biochem. Pharmacol. 54, 1281.
      Lin, Y.-L., and Lin, J.-K. 1997. Mol. Pharmacol. 52, 465.
      Fiala, E.S., et al. 1996. Experientia 52, 922.
      Katiyar, S.K., et al. 1995. J. Invest. Dermatol. 105, 394.
      Liao, S., et al. 1995. Cancer Lett. 96, 239.
      Yamane, T., et al. 1995. Cancer Res. 55, 2081.
      Huang, M.T., et al. 1992. Carcinogenesis 13, 947.